SECTOR : TechBio
ENTRY DATE : 2023
BUSINESS: Venture Capital
WEB : https://diogenx.com/

DiogenX

DiogenX, is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators for the treatment of type one diabetes (T1D).

DiogenX’ lead program is a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells. To date, the company has achieved in vivo proof of concept demonstrating efficacy in prevention and reversion settings and an unprecedented effect on human beta cell mass generation, leading to increased functional insulin-producing beta cells. In addition, long term exposure to the drug was well tolerated in all preclinical models and showed the unique ability to safely modulate the Wnt/β-catenin pathway. This collective data suggests the potential for broad clinical utility, in monotherapy and in combination with insulins and therapies that replace or protect beta cells.